Effects of low-dose atorvastatin and rosuvastatin on plasma lipid profiles: A long-term, randomized, open-label study in patients with primary hypercholesterolemia

American Journal of Cardiovascular Drugs

Volumn 8, Issue 4, 2008, Pages 265-270

  Mazza, Fabio ^a   Stefanutti, Claudia ^a   Di Giacomo, Serafina ^a   Vivenzio, Antonio ^a   Fraone, Nadia ^a   Mazzarella, Bruno ^a   Bucci, Antonello ^a  

^a POLICLINICO UMBERTO I   (Italy)

Author keywords

Atorvastatin, therapeutic use; Cardiovascular disorders, prevention; HMG CoA reductase inhibitors, therapeutic use; LDL cholesterol; Lipid metabolism disorders, treatment; Primary hypercholesterolaemia, treatment; Rosuvastatin, therapeutic use

Indexed keywords

ALANINE AMINOTRANSFERASE; ASPARTATE AMINOTRANSFERASE; ATORVASTATIN; CREATINE; CREATINE KINASE; FIBRINOGEN; GAMMA GLUTAMYLTRANSFERASE; LIPID; LOW DENSITY LIPOPROTEIN CHOLESTEROL; NITROGEN; ROSUVASTATIN; TRIACYLGLYCEROL;

ADULT; AGED; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ARTICLE; ATHEROGENESIS; CHOLESTEROL BLOOD LEVEL; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG EFFECT; DRUG EFFICACY; DRUG TOLERABILITY; FEMALE; HIGH RISK PATIENT; HUMAN; HYPERCHOLESTEROLEMIA; LIPID ANALYSIS; LIPID BLOOD LEVEL; LOW DRUG DOSE; MAJOR CLINICAL STUDY; MALE; PATIENT SAFETY; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SIDE EFFECT; TRIACYLGLYCEROL BLOOD LEVEL;

ADULT; AGED; CHOLESTEROL; CHOLESTEROL, LDL; FEMALE; FLUOROBENZENES; FOLLOW-UP STUDIES; HEPTANOIC ACIDS; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; HYPERCHOLESTEROLEMIA; MALE; MIDDLE AGED; PYRIMIDINES; PYRROLES; SULFONAMIDES; TRIGLYCERIDES;

EID: 49449117960     PISSN: 11753277     EISSN: None     Source Type: Journal    
DOI: 10.2165/00129784-200808040-00006     Document Type: Article

References (21)

1. Grundy SM, Cleeman JI, Merz CN, et al. Implication of recent clinical trials for the National Cholesterol Education Program Adult Treatment panel III guidelines [published erratum appears in Circulation 2004;110 (6):763]. Circulation 2004; 110: 227-39
2. Expert Panel on Detection Evaluation and treatment of High Blood Cholesterol in Adults. Executive Summary of the Third report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adults Treatments Panel III). JAMA 2001; 285: 2486-97
3. Sever PS, Dhalof B, Poulter NR, et al., on behalf of the ASCOT investigators. Prevention of coronary and stroke events with atorvastatin in hypertensive patients who have average or lower-than-average cholesterol concentrations, in the Anglo Scandinavian Cardiac Outcomes Trial lipid Lowering Arm: (ASCOT-LLA) a multicentre randomised controlled trial. Lancet 2003; 361: 1149-58
4. Schuster H, Barter PJ, Stender S, et al. Effect of switching statin on achievement of lipid goals: Measuring Effective Reduction in Cholesterol using Rosuvastatin Therapy (MERCURY I) study. Am Heart J 2004; 147: 705-12
5. Olsson AG, Istad H, Luurila O, et al. Effect of rosuvastatin and atorvastatin compared over 52 weeks of treatment in patients with hypercholesterolemia. Am Heart J 2002; 144: 1044-51
6. Shepherd J, Hunninghake DB, Stein EA, et al. Safety of rosuvastatin. Am J Cardiol 2004; 94: 882-8
7. Rodenburg J, Vissers MN, Wiegman A, et al. Statin treatment in children with familial hypercholesterolemia: the younger, the better. Circulation 2007; 116: 664-8
8. Saltissi D, Westhuyzen J, Morgan C, et al. Efficacy, safety and tolerability of atorvastatin in dyslipidemic subjects with advanced (non-nephrotic) and end-stage chronic renal failure. Clin Exp Nephrol 2006; 10: 201-9
9. Schwartz GG, Bolognese MA, Tremblay BP, et al. Efficacy and safety of rosuvastatin and atorvastatin in patients with hypercholesterolemia and high risk of coronary heart disease: a randomised, controlled trial. Am Heart J 2004; 148: (1): H1-9
10. Olsson AG, McTaggart F, Raza A. Rosuvastatin a highly effective new HMG-CoA reductase inhibitor. Cardiovasc Drug Rev 2002; 20: 303-28
11. McKenney JM. Efficacy and safety of rosuvastatin in treatment of dyslipidemia. Am J Health Syst Pharma 2005; 62: 1033-47
12. Schwartz GG, Olsson AG, Ezekowitz MD, et al. Effect of atorvastatin on early recurrent ischemic events in acute coronary syndromes: the MIRACL study. A randomised controlled trial. JAMA 2001; 285: 1711-8
13. Davidson M, Ma P, Stein EA, et al. Comparison of effects on low-density lipoprotein cholesterol and high-density lipoprotein cholesterol with rosuvastatin versus atorvastatin in patients with type IIa or IIb hypercholesterolemia. Am J Cardiol 2002; 89: 268-75
14. Cheng JW. Rosuvastatin in the management of hyperlipidemia. Clin Ther 2004; 103: 1368-87
15. Clearfield M, Amerena J, Bassand J-P, et al. Comparison of the efficacy and safety of rosuvastatin 10mg and atorvastatin 20mg in high-risk patients with hypercholesterolemia. Prospective Study to evaluate the use of low doses of the Statin Atorvastatin and Rosuvastatin (PULSAR). Trials 2006; 7: 35
16. Friedewald WT, Levy RI, Fredrickson DS. Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge. Clin Chem 1972; 18: 499-502
17. Cheung RC, Morrell JM, Kallend D, et al. Effects of switching statins on lipid and apolipoprotein ratios in the MERCURY I study. Int J Cardiol 2005 Apr 20; 100: 309-16
18. Deedwania PC, Hunninghake DB, Bays HE, et al., for the STELLAR Study Group. Effects of rosuvastatin, atorvastatin, simvastatin, and pravastatin on atherogenic dyslipidemia in patients with characteristics of the metabolic syndrome. Am J Cardiol 2005; 95: 360-6
19. Schuster H, Fox JC. Investigating Cardiovascular risk reduction: the rosuvastatin GALAXY Programme. Expert Opin Pharmacother 2004; 5: 1188-200
20. Kapur NK. Rosuvastatin: a highly potent statin for the prevention and managment of coronary artery desease. Expert Rev Cardiovasc Ther 2007; 5: 161-75
21. Hirsch M, O'Donnell J. Rosuvastatin is cost effective compared with atorvastatin in reaching cholesterol goals. Int J Clin Pract 2005; 104: 251-6